BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cerebrolysin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cerebrolysin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06899464-757@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cerebrolysin: Phase 4 readout est. (NCT06899464)
DESCRIPTION:Cerebrolysin\, phase 4.\nStudy: Safety and Feasibility of Using
  Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Pro
 spective Randomized Open Blinded End-point Trial\nEstimated primary comple
 tion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cerebrolysin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06899464
URL:https://assetmemo.bio/drug/cerebrolysin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043686-757@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Cerebrolysin: Phase na readout est. (NCT07043686)
DESCRIPTION:Cerebrolysin\, phase na.\nStudy: Cerebrolysin in Early Stroke R
 ehabilitation - Tertiary Study\nEstimated primary completion: 15 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cerebrolysin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07043686
URL:https://assetmemo.bio/drug/cerebrolysin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846488-757@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cerebrolysin: Phase na readout est. (NCT07846488)
DESCRIPTION:Cerebrolysin\, phase na.\nStudy: Combined Acupuncture-Based The
 rapy for Rehabilitation After Ischemic Stroke\nEstimated primary completio
 n: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cere
 brolysin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07846488
URL:https://assetmemo.bio/drug/cerebrolysin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339411-757@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cerebrolysin: Phase 2 readout est. (NCT06339411)
DESCRIPTION:Cerebrolysin\, phase 2.\nStudy: Cerebrolysin After Reperfusion 
 in Extended-window EndoVascular Thrombectomy\nEstimated primary completion
 : 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 erebrolysin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06339411
URL:https://assetmemo.bio/drug/cerebrolysin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
